S100A9通过诱导IL-23/3型免疫驱动银屑病样炎症慢性化
该研究结合多个转录组数据集分析、人银屑病皮肤单细胞图谱和骨髓嵌合小鼠实验,发现S100A9在银屑病皮损中上调,角质形成细胞是其主要来源;S100A9诱导树突状细胞产生IL-23,驱动IL-23/3型免疫,而IL-23/IL-17轴又诱导表皮S100A9表达,形成自身调节环路,促进银屑病慢性化。
要点
- S100A9是银屑病皮损中上调最显著的基因之一,角质形成细胞为主要来源。
- 遗传敲除或药物抑制S100A9可减轻Aldara诱导的小鼠皮肤炎症。
- 角质形成细胞来源的S100A9与IL-23/3型免疫形成自身调节环路,驱动炎症慢性化。
核心结论
- 角质形成细胞来源的S100A9与IL-23/3型免疫在银屑病样炎症中形成自身调节环路,S100A9在银屑病慢性化中起关键作用。
研究设计与样本
- 研究结合多个转录组数据集的系统分析、人银屑病皮肤单细胞图谱分析、骨髓嵌合小鼠实验及临床前银屑病样皮肤炎症模型。
主要发现
- S100A9是人银屑病皮肤中上调最显著的基因之一,并在银屑病患者皮损和临床前银屑病样皮肤炎症模型中得到证实。
- 遗传敲除或药物抑制S100A9可减轻Aldara诱导的皮肤炎症。
- 单细胞图谱和骨髓嵌合小鼠实验确定角质形成细胞是S100A9的主要来源。
- S100A9诱导树突状细胞产生IL-23,驱动银屑病样皮肤炎症中的IL-23/3型免疫。
- 皮肤IL-23/IL-17轴在人及实验性银屑病中诱导表皮S100A9表达。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Psoriasis is a chronic inflammatory skin disorder driven by the IL-23/type 3 immune response. However, molecular mechanisms sustaining the chronicity of inflammation and psoriatic lesions remain elusive. Combining systematic analyses of several transcriptomic datasets, we delineated gene signatures across human psoriatic skin, identifying S100A9 as one of the most up-regulated genes, which was confirmed in lesioned skin from patients with psoriasis and preclinical psoriasiform skin inflammation models. Genetic ablation or pharmacologic inhibition of S100A9 alleviated Aldara-induced skin inflammation. By single-cell mapping of human psoriatic skin and bone marrow chimeric mice experiments, we identified keratinocytes as the major source of S100A9. Mechanistically, S100A9 induced IL-23 production by dendritic cells, driving the IL-23/type 3 immunity in psoriasiform skin inflammation. In addition, the cutaneous IL-23/IL-17 axis induced epidermal S100A9 expression in human and experimental psoriasis. Thus, we showed an autoregulatory circuit between keratinocyte-derived S100A9 and IL-23/type 3 immunity during psoriasiform inflammation, identifying a crucial function of S100A9 in the chronification of psoriasis.
引用
- Silva de Melo BM, Veras FP, Zwicky P, et al. S100A9 Drives the Chronification of Psoriasiform Inflammation by Inducing IL-23/Type 3 Immunity. J Invest Dermatol. 2023. PMID: 36921684. doi:10.1016/j.jid.2023.02.026
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。